T1	intervention 0 11	Anastrozole
T2	duration 462 499	Between Feb 2, 2003, and Jan 31, 2012
T3	eligibility 514 534	postmenopausal women
T4	average-age 540 551	40-70 years
T5	eligibility 676 710	at increased risk of breast cancer
T6	control 875 882	placebo
T7	duration 897 904	5 years
T8	outcome-Measure 1152 1250	histologically confirmed breast cancer (invasive cancers or non-invasive ductal carcinoma in situ)
T9	intervention-participants 1343 1347	1920
T10	control-participants 1404 1408	1944
T11	outcome 1550 1573	developed breast cancer
T12	intervention-value 1474 1476	40
T13	intervention-value 1509 1511	2%
T14	control-value 1517 1519	85
T15	control-value 1542 1544	4%
T16	outcome 1637 1693	cumulative incidence of all breast cancers after 7 years
T17	control-value 1698 1702	5·6%
T18	intervention-value 1728 1732	2·8%
T19	intervention-value 1759 1761	18
T20	outcome 1762 1768	deaths
T21	control-value 1812 1814	17
